The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study.

@article{Quartuccio2014The1F,
  title={The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study.},
  author={Luca Quartuccio and Martina Fabris and Elena Pontarini and Sara Salvin and Alen Zabotti and Maurizio Benucci and Mariangela Manfredi and Domenico Biasi and Viviana Ravagnani and Fabiola Atzeni and Piercarlo Sarzi-Puttini and Pia Morassi and Fabio Fischetti and Paola Tomietto and Laura Maria Bazzichi and Marta Saracco and Raffaele A Pellerito and Marco Amedeo Cimmino and Franco Schiavon and Valeria Carraro and Angelo Semeraro and Roberto Caporali and Lorenzo Cavagna and Roberto Bortolotti and Giuseppe Paolazzi and Marcello Govoni and Stefano Bombardieri and Salvatore de Vita},
  journal={Annals of the rheumatic diseases},
  year={2014},
  volume={73 4},
  pages={716-21}
}
OBJECTIVE The polymorphism 158V/F of Fc fragment of IgG (FCGR) type 3A may influence the response to rituximab (RTX) in rheumatoid arthritis (RA). We investigated the FCG3A polymorphism in a large cohort of RA patients treated with RTX, also by considering the possible loss of response from month +4 to +6 after RTX and the presence of established predictors of response. METHODS The study analysed 212 RA patients. European League Against Rheumatism (EULAR) response was evaluated at months +4… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 19 extracted citations

Similar Papers

Loading similar papers…